Breast Cancer Screening in Denmark

Letters3 October 2017Breast Cancer Screening in DenmarkSameer Bhargava, MD, Kaitlyn Tsuruda, MSc, and Solveig Hofvind, PhDSameer Bhargava, MDFrom Cancer Registry of Norway, Oslo, Norway.Search for more papers by this author, Kaitlyn Tsuruda, MScFrom Cancer Registry of Norway, Oslo, Norway.Search for more papers by this author, and Solveig Hofvind, PhDFrom Cancer Registry of Norway, Oslo, Norway.Search for more papers by this authorAuthor, Article, and Disclosure Informationhttps://doi.org/10.7326/L17-0269 SectionsAboutFull TextPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissions ShareFacebookTwitterLinkedInRedditEmail TO THE EDITOR:Jørgensen and colleagues (1) conclude that the incidence of advanced-stage breast cancer did not decrease in Denmark after the introduction of organized screening. They further report an overdiagnosis rate of 48.3% and suggest that up to one third of cases of ductal carcinoma in situ and invasive breast cancer in Danish women aged 50 to 69 years were overdiagnosed. On the basis of their results, the authors claim that screening has not reduced mortality; however, this statement contradicts results from a Danish study from 2015 (2). That Denmark has, for more than 50 years, had the highest ...References1. Jørgensen KJ, Gøtzsche PC, Kalager M, Zahl PH. Breast cancer screening in Denmark: a cohort study of tumor size and overdiagnosis. Ann Intern Med. 2017;166:313-23. [PMID: 28114661]. doi:10.7326/M16-0270 LinkGoogle Scholar2. Njor SH, Schwartz W, Blichert-Toft M, Lynge E. Decline in breast cancer mortality: how much is attributable to screening? J Med Screen. 2015;22:20-7. [PMID: 25492943] doi:10.1177/0969141314563632 CrossrefMedlineGoogle Scholar3. Tryggvadóttir L, Gislum M, Bray F, Klint A, Hakulinen T, Storm HH, et al. Trends in the survival of patients diagnosed with breast cancer in the Nordic countries 1964-2003 followed up to the end of 2006. Acta Oncol. 2010;49:624-31. [PMID: 20429724] doi:10.3109/02841860903575323 CrossrefMedlineGoogle Scholar4. Marmot MG, Altman DG, Cameron DA, Dewar JA, Thompson SG, Wilcox M. The benefits and harms of breast cancer screening: an independent review. Br J Cancer. 2013;108:2205-40. [PMID: 23744281] doi:10.1038/bjc.2013.177 CrossrefMedlineGoogle Scholar5. Puliti D, Duffy SW, Miccinesi G, de Koning H, Lynge E, Zappa M, et al; EUROSCREEN Working Group. Overdiagnosis in mammographic screening for breast cancer in Europe: a literature review. J Med Screen. 2012;19 Suppl 1:42-56. [PMID: 22972810] CrossrefMedlineGoogle Scholar Author, Article, and Disclosure InformationAffiliations: From Cancer Registry of Norway, Oslo, Norway.Disclosures: Disclosures can be viewed at www.acponline.org/authors/icmje/ConflictOfInterestForms.do?msNum=L17-0269. PreviousarticleNextarticle Advertisement FiguresReferencesRelatedDetailsSee AlsoBreast Cancer Screening in Denmark Karsten Juhl Jørgensen , Peter C. Gøtzsche , Mette Kalager , and Per-Henrik Zahl Breast Cancer Screening in Denmark Karsten Juhl Jørgensen , Peter C. Gøtzsche , Mette Kalager , and Per-Henrik Zahl Breast Cancer Screening in Denmark Tony H.H. Chen and Stephen W. Duffy Breast Cancer Screening in Denmark Changjun Wang , Yidong Zhou , Feng Mao , Yan Lin , and Qiang Sun Metrics 3 October 2017Volume 167, Issue 7Page: 523KeywordsBreast cancerBreast cancer screeningDisclosureDuctal carcinoma in situMortality ePublished: 3 October 2017 Issue Published: 3 October 2017 Copyright & PermissionsCopyright © 2017 by American College of Physicians. All Rights Reserved.PDF downloadLoading ...